These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38066574)

  • 1. Long-term Sudan Virus Ebola Survivors Maintain Multiple Antiviral Defense Mechanisms.
    Sobarzo A; Moné Y; Lang S; Gelkop S; Brangel P; Kuehne AI; McKendry RA; Mell JC; Ahmed A; Davis C; Dye JM; Lutwama JJ; Lobel L; Veas F; Ehrlich GD
    J Infect Dis; 2024 Aug; 230(2):426-437. PubMed ID: 38066574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.
    Sobarzo A; Stonier SW; Radinsky O; Gelkop S; Kuehne AI; Edri A; Herbert AS; Fedida-Metula S; Lutwama JJ; Yavelsky V; Davis C; Porgador A; Dye JM; Lobel L
    EBioMedicine; 2019 Aug; 46():215-226. PubMed ID: 31326432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune memory to Sudan virus: comparison between two separate disease outbreaks.
    Sobarzo A; Eskira Y; Herbert AS; Kuehne AI; Stonier SW; Ochayon DE; Fedida-Metula S; Balinandi S; Kislev Y; Tali N; Lewis EC; Lutwama JJ; Dye JM; Yavelsky V; Lobel L
    Viruses; 2015 Jan; 7(1):37-51. PubMed ID: 25569078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors.
    Sobarzo A; Stonier SW; Herbert AS; Ochayon DE; Kuehne AI; Eskira Y; Fedida-Metula S; Tali N; Lewis EC; Egesa M; Cose S; Lutwama JJ; Yavelsky V; Dye JM; Lobel L
    Viruses; 2016 May; 8(5):. PubMed ID: 27187443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
    Sobarzo A; Groseth A; Dolnik O; Becker S; Lutwama JJ; Perelman E; Yavelsky V; Muhammad M; Kuehne AI; Marks RS; Dye JM; Lobel L
    J Infect Dis; 2013 Jul; 208(2):299-309. PubMed ID: 23585686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 7. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.
    Thom R; Tipton T; Strecker T; Hall Y; Akoi Bore J; Maes P; Raymond Koundouno F; Fehling SK; Krähling V; Steeds K; Varghese A; Bailey G; Matheson M; Kouyate S; Coné M; Moussa Keita B; Kouyate S; Richard Ablam A; Laenen L; Vergote V; Guiver M; Timothy J; Atkinson B; Ottowell L; Richards KS; Bosworth A; Longet S; Mellors J; Pannetier D; Duraffour S; Muñoz-Fontela C; Sow O; Koivogui L; Newman E; Becker S; Sprecher A; Raoul H; Hiscox J; Henao-Restrepo AM; Sakoba K; Magassouba N; Günther S; Kader Konde M; Carroll MW
    Lancet Infect Dis; 2021 Apr; 21(4):507-516. PubMed ID: 33065039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
    Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice.
    Xu S; Jiao C; Jin H; Li W; Li E; Cao Z; Shi Z; Yan F; Zhang S; He H; Chi H; Feng N; Zhao Y; Gao Y; Yang S; Wang J; Wang H; Xia X
    Viruses; 2019 Dec; 11(12):. PubMed ID: 31835785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI.
    Radinsky O; Edri A; Brusilovsky M; Fedida-Metula S; Sobarzo A; Gershoni-Yahalom O; Lutwama J; Dye J; Lobel L; Porgador A
    Sci Rep; 2017 Jul; 7(1):6054. PubMed ID: 28729706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.
    Gunn BM; Lu R; Slein MD; Ilinykh PA; Huang K; Atyeo C; Schendel SL; Kim J; Cain C; Roy V; Suscovich TJ; Takada A; Halfmann PJ; Kawaoka Y; Pauthner MG; Momoh M; Goba A; Kanneh L; Andersen KG; Schieffelin JS; Grant D; Garry RF; Saphire EO; Bukreyev A; Alter G
    Immunity; 2021 Apr; 54(4):815-828.e5. PubMed ID: 33852832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses.
    Gunn BM; Roy V; Karim MM; Hartnett JN; Suscovich TJ; Goba A; Momoh M; Sandi JD; Kanneh L; Andersen KG; Shaffer JG; Schieffelin JS; Garry RF; Grant DS; Alter G
    J Infect Dis; 2020 Jan; 221(1):156-161. PubMed ID: 31301137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay.
    Sobarzo A; Perelman E; Groseth A; Dolnik O; Becker S; Lutwama JJ; Dye JM; Yavelsky V; Lobel L; Marks RS
    Clin Vaccine Immunol; 2012 Nov; 19(11):1844-52. PubMed ID: 22993411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors.
    Bramble MS; Hoff N; Gilchuk P; Mukadi P; Lu K; Doshi RH; Steffen I; Nicholson BP; Lipson A; Vashist N; Sinai C; Spencer D; Olinger G; Wemakoy EO; Illunga BK; Pettitt J; Logue J; Marchand J; Varughese J; Bennett RS; Jahrling P; Cavet G; Serafini T; Ollmann Saphire E; Vilain E; Muyembe-Tamfum JJ; Hensely LE; Simmons G; Crowe JE; Rimoin AW
    J Infect Dis; 2018 Nov; 218(12):1929-1936. PubMed ID: 30107445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting severe immune dysfunction in Ebola virus disease survivors.
    Wiedemann A; Foucat E; Hocini H; Lefebvre C; Hejblum BP; Durand M; Krüger M; Keita AK; Ayouba A; Mély S; Fernandez JC; Touré A; Fourati S; Lévy-Marchal C; Raoul H; Delaporte E; Koivogui L; Thiébaut R; Lacabaratz C; Lévy Y;
    Nat Commun; 2020 Jul; 11(1):3730. PubMed ID: 32709840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
    Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Woolsey C; Borisevich V; Agans KN; Fenton KA; Cross RW; Geisbert TW
    mBio; 2021 Aug; 12(4):e0151721. PubMed ID: 34372693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
    Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
    Front Immunol; 2021; 12():706757. PubMed ID: 34335620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
    Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
    Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.